Consolidated Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity - USD ($) $ in Thousands	Total	Revision of Prior Period, Accounting Standards Update, Adjustment	Convertible Preferred Stock	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive (Loss) Gain	Accumulated Deficit	Accumulated Deficit Revision of Prior Period, Accounting Standards Update, Adjustment	Noncontrolling Interest
Beginning Balance at Dec. 31, 2018	$ (258,112)			$ 1	$ 37,902	$ (107)	$ (295,908)
Beginning Balance, Shares at Dec. 31, 2018				12,841,536
Convertible preferred stock, Beginning Balance at Dec. 31, 2018			$ 560,858
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2018			92,790,094
Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us	320,850			$ 2	320,848
Proceeds from initial public offering, net of underwriters' discounts and commissions, Shares				17,250,000
Initial public offering costs	(4,986)				(4,986)
Conversion of convertible preferred stock to common stock	561,931		$ (561,931)	$ 9	561,922
Conversion of convertible preferred stock to common stock, Shares			(93,039,737)	93,039,737
Conversion of convertible preferred stock warrant to common stock warrant	2,602				2,602
Issuance of common stock upon exercise of common stock warrants	9				9
Issuance of common stock upon exercise of common stock warrants, Shares				54,792
Issuance of common stock for cash upon exercise of stock options	4,413				4,413
Issuance of common stock for cash upon exercise of stock options, Shares				2,043,767
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value			$ 109
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares			249,643
Vesting of restricted stock units				8,310
Change in redemption value for vested Series E-1 convertible preferred stock options	(964)						(964)
Change in redemption value for vested Series E-1 convertible preferred stock options			$ 964
Common stock option and restricted stock unit share-based compensation	13,124				13,124
Other comprehensive income (loss)	778					778
Net loss	(68,606)						(68,606)
Ending Balance at Dec. 31, 2019	571,039	$ 93		$ 12	935,834	671	(365,478)	$ 93
Ending Balance, Shares at Dec. 31, 2019				125,238,142
Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us	$ 271,839			$ 1	271,838
Proceeds from initial public offering, net of underwriters' discounts and commissions, Shares				7,200,000
Accounting Standards Update Extensible List	ASC 842
Issuance of common stock for cash upon exercise of stock options	$ 21,539			$ 1	21,538
Issuance of common stock for cash upon exercise of stock options, Shares				5,204,254
Vesting of restricted stock units				4,500
Common stock option and restricted stock unit share-based compensation	24,761				24,761
Other comprehensive income (loss)	222					222
Net loss	(146,227)						(146,227)
Ending Balance at Dec. 31, 2020	743,266			$ 14	1,253,971	893	(511,612)
Ending Balance, Shares at Dec. 31, 2020				137,646,896
Issuance of common stock upon exercise of common stock warrants, Shares				54,162
Issuance of common stock for cash upon exercise of stock options	$ 26,484				26,484
Issuance of common stock for cash upon exercise of stock options, Shares	3,674,057			3,674,057
Vesting of restricted stock units				18,750
Common stock option and restricted stock unit share-based compensation	$ 43,251				43,251
Capital contributions for Digital Biotechnologies, Inc.	429				300				$ 129
Other comprehensive income (loss)	(2,030)					(2,030)
Net loss	(207,298)						(207,279)		(19)
Ending Balance at Dec. 31, 2021	$ 604,102			$ 14	$ 1,324,006	$ (1,137)	$ (718,891)		$ 110
Ending Balance, Shares at Dec. 31, 2021				141,393,865